P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

Detalles Bibliográficos
Autores principales: Usmani, S., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B., Valent, J., Rosenzweig, M., Zonder, J., Dhodapkar, M., Callander, N., Zimmerman, T., Voorhees, P., Durie, B., Rajkumar, S. V., Richardson, P., Orlowski, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430248/
http://dx.doi.org/10.1097/01.HS9.0000846728.05693.f8
_version_ 1784779708771074048
author Usmani, S.
Hoering, A.
Ailawadhi, S.
Sexton, R.
Lipe, B.
Valent, J.
Rosenzweig, M.
Zonder, J.
Dhodapkar, M.
Callander, N.
Zimmerman, T.
Voorhees, P.
Durie, B.
Rajkumar, S. V.
Richardson, P.
Orlowski, R.
author_facet Usmani, S.
Hoering, A.
Ailawadhi, S.
Sexton, R.
Lipe, B.
Valent, J.
Rosenzweig, M.
Zonder, J.
Dhodapkar, M.
Callander, N.
Zimmerman, T.
Voorhees, P.
Durie, B.
Rajkumar, S. V.
Richardson, P.
Orlowski, R.
author_sort Usmani, S.
collection PubMed
description
format Online
Article
Text
id pubmed-9430248
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94302482022-08-31 P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211) Usmani, S. Hoering, A. Ailawadhi, S. Sexton, R. Lipe, B. Valent, J. Rosenzweig, M. Zonder, J. Dhodapkar, M. Callander, N. Zimmerman, T. Voorhees, P. Durie, B. Rajkumar, S. V. Richardson, P. Orlowski, R. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430248/ http://dx.doi.org/10.1097/01.HS9.0000846728.05693.f8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Usmani, S.
Hoering, A.
Ailawadhi, S.
Sexton, R.
Lipe, B.
Valent, J.
Rosenzweig, M.
Zonder, J.
Dhodapkar, M.
Callander, N.
Zimmerman, T.
Voorhees, P.
Durie, B.
Rajkumar, S. V.
Richardson, P.
Orlowski, R.
P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title_full P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title_fullStr P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title_full_unstemmed P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title_short P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
title_sort p965: follow-up analysis of the randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (swog-1211)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430248/
http://dx.doi.org/10.1097/01.HS9.0000846728.05693.f8
work_keys_str_mv AT usmanis p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT hoeringa p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT ailawadhis p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT sextonr p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT lipeb p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT valentj p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT rosenzweigm p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT zonderj p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT dhodapkarm p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT callandern p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT zimmermant p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT voorheesp p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT durieb p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT rajkumarsv p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT richardsonp p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211
AT orlowskir p965followupanalysisoftherandomizedphaseiitrialofbortezomiblenalidomidedexamthasonewithwithoutelotuzumabfornewlydiagnosedhighriskmultiplemyelomaswog1211

Ejemplares similares